Brief: Natco Pharma Says Submission Of ANDA With FDA For Generic Version Of Tabrecta
29/08/2024 11:32
Aug 29 (Reuters) - Natco Pharma Ltd NATP.NS :
* NATCO PHARMA - SUBMISSION OF ANDA WITH FDA FOR GENERIC
VERSION
OF TABRECTA
* NATCO PHARMA - SUBMISSION OF ABBREVATED NEW DRUG
APPLICATION
(ANDA)
Further company coverage: NATP.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees